1. Opening Hook
You know Indian med-tech is heating up when even MRI machines start sounding like SaaS products—AI-enabled, cloud-connected, preventive-care infused, and of course, “affordable.” While global giants still sell machines priced like private jets, Fischer Medical Ventures (FMV) seems to be selling MRIs that don’t require selling kidneys.
And then they casually drop a 118% revenue growth bomb, as if doubling is something they do between breakfast and lunch.
Oh, and they’re net cash. Yes, in med-tech. Read on—because this call gets absolutely wild later.
2. At a Glance
- Revenue up 118% – MRI + Preventive Healthcare went full “Gym Bulk Mode.”
- EBITDA margin at 21% (H1: 25%) – Management says “operating leverage.” Others call it wizardry.
- PAT up 107x – Because apparently compounding is real and scary.
- Exports now 30% – They finally found passports.
- Net cash ₹28 crore – CFO flexed this at least thrice.
- Debt-to-equity 0.04 – Ultra-lean. Almost emotional.
3. Management’s Key Commentary (Quotes + Sarcastic Translations)
1. “India’s healthcare is shifting from disease care to early detection.”
(Translation: Too many people wait for medical problems to become Netflix thrillers.)
2. “We built India’s first and only accredited Make-in-India MRI.”
(Translation: Import substitution: 1. Global OEMs: 0 😏)
3. “CT scanners, intra-op MRIs, and AI-based diagnostics are next.”
(Translation: We’re not stopping at MRIs; we want the whole hospital.)
4. “Preventive healthcare contributed the larger half of revenue this year.”
(Translation: People want to avoid hospitals more than ever, and we’re monetizing it beautifully.)
5. “Our MRI capex is 20–35% cheaper than GE/Siemens.”
(Translation: German machines cost German money. Ours don’t.)
6. “We have a strong order book but cannot disclose numbers.”
(Translation: Trust us. The orders exist. Somewhere. Probably.)
7. “We expect 15–20% domestic MRI market share soon.”
(Translation: Someone check on Philips; they might be sweating.)
4. Numbers Decoded
-------------------------------------------------------------------
Metric Q2 FY25 Q2 FY26 YoY
-------------------------------------------------------------------
Revenue (₹ cr) 40 86 +118%
H1 Revenue (₹ cr) 50 110 +120%
Gross Margin (₹ cr) 3.5 25 7x
Gross Margin % 9% 28% Crowned
EBITDA (₹ cr) 0.7 19 25x
EBITDA Margin 2% 21% Shockers
PAT (₹ cr) 0.3 14 46x
Net Cash (₹ cr) — 28 Flex Mode
Exports % ~8% ~30% Global now
-------------------------------------------------------------------
One-liners:
- Preventive healthcare is the new hero; MRIs are the sturdy sidekick.
- Margins expanded faster than AI hype cycles.
- Revenue graph must look like a moon mission trajectory.
5. Analyst Questions (Summaries + Humorous Translations)
Q: What’s your core expertise?
A: Radiology + Preventive AI + Connected healthcare.
(Translation: We do hardware, software, buzzwords—everything.)
Q: What’s the MRI pricing advantage vs GE/Siemens?
A: 20–35% cheaper on capex, 10–15% cheaper on opex.
(Translation: Premium results, budget tension.)
Q: TAM and target share?
A: India = 500 MRIs/year expanding to 1000; we want 15–20% share.
(Translation: “Bhai, we want a seat at the big boys’ table.”)
Q: School health kiosks revenue model?
A: Subscription.
(Translation: Even your kid’s school is now SaaS.)
Q: Nanomedic wound-care update?
A: Pilot done, awaiting CDSCO approval.
(Translation: Regulatory gods willing, we launch soon.)
6. Guidance & Outlook
FMV politely refused numeric guidance, but here’s what they basically implied:
- Preventive healthcare and diagnostic imaging will be 50:50 revenue split in 2–3 years.
- Industry fundamentals (PLI, Ayushman Bharat, Make-in-India) act like tailwinds on steroids.
- FY27–FY28 will be scale years with CT, intra-op MRIs, new
